TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative have announced a collaboration to evaluate TransCode's lead therapeutic candidate, TTX-MC138, within the PRE-I-SPY Phase 2a clinical trial platform. This partnership represents a significant step in addressing the challenge of cancer recurrence in patients who have completed standard curative-intent therapy but remain at high risk.
The trial plans to enroll up to 45 colorectal cancer patients who are ctDNA positive following standard treatment. Scheduled to begin in the first half of 2026, the study will be led by Dr. Paula Pohlmann of MD Anderson Cancer Center. It will assess the biological and clinical activity of TTX-MC138 specifically in the minimal residual disease setting, where the risk of recurrence is high and therapeutic options are currently limited.
This collaboration reflects the growing interest in precision treatments targeting micrometastatic disease, which refers to small clusters of cancer cells that may remain after initial treatment and can lead to recurrence. TTX-MC138 is an RNA therapeutic candidate focused on treating metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode Therapeutics is a clinical-stage company pioneering immunoncology and RNA therapeutic treatments for high-risk and advanced cancers.
The importance of this trial lies in its potential to address a critical gap in cancer care. For patients who have undergone curative-intent therapy but show evidence of minimal residual disease through ctDNA positivity, there are few effective options to prevent recurrence. The PRE-I-SPY trial platform, through this collaboration, aims to evaluate whether TTX-MC138 can provide a meaningful therapeutic benefit in this challenging clinical scenario.
For investors and stakeholders following TransCode Therapeutics, the latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ. The broader implications of this collaboration extend beyond the specific trial, potentially paving the way for new approaches in cancer treatment that target residual disease before it becomes clinically apparent metastasis.
This announcement comes through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. For more information about InvestorWire's services, visit https://www.InvestorWire.com. The full terms of use and disclaimers applicable to all content provided by InvestorWire are available at https://www.InvestorWire.com/Disclaimer.
